These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

808 related items for PubMed ID: 23545756

  • 21. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S, Uriel N, Yarmohammadi H, Holley CT, Feng A, Roy SS, Reding MT, John R, Eckman P, Zantek ND.
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [Abstract] [Full Text] [Related]

  • 24. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, Rodriquez D, Weinstein S.
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Evaluation of weight-based dosing of unfractionated heparin in obese children.
    Taylor BN, Bork SJ, Kim S, Moffett BS, Yee DL.
    J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664
    [Abstract] [Full Text] [Related]

  • 28. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS, Menon V, Schappert J, Wilentz JR, Singh V, Hochman JS.
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [Abstract] [Full Text] [Related]

  • 29. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
    Schechter T, Finkelstein Y, Ali M, Kahr WH, Williams S, Chan AK, Deveber G, Brandão LR.
    J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
    [Abstract] [Full Text] [Related]

  • 30. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P, Boutière B, Horellou MH, Trzeciak MC, Samama MM.
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [Abstract] [Full Text] [Related]

  • 31. Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys.
    Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA.
    Thromb Haemost; 2010 Oct; 104(4):837-44. PubMed ID: 20664895
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennett M, Horton S, Shann F, Lane G, Ross-Smith M, Monagle P.
    Thromb Res; 2007 Oct; 120(3):347-51. PubMed ID: 17118432
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
    Adatya S, Sunny R, Fitzpatrick MJ, Colvin M, Thennapan T, John R, Dodge Zantek N, Pritzker M, Eckman P, Uriel N.
    J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Evaluating unfractionated heparin fixed dosing protocol and establishing an institutional therapeutic range for UFH in hospital setting in Jordan.
    Tahaineh L, Albsoul-Younes A, Iflaifel M, Shehabi I.
    Clin Appl Thromb Hemost; 2014 Jan; 20(1):73-7. PubMed ID: 22949741
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.